Scinai Immunotherapeutics Statistics
Total Valuation
SCNI has a market cap or net worth of $2.03 million. The enterprise value is $2.48 million.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SCNI has 3.47 million shares outstanding. The number of shares has increased by 189.55% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 3.47M |
| Shares Change (YoY) | +189.55% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 11.99% |
| Owned by Institutions (%) | 5.23% |
| Float | 3.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.43 |
| Forward PS | n/a |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.30, with a Debt / Equity ratio of 0.28.
| Current Ratio | 1.30 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -21.01 |
Financial Efficiency
Return on equity (ROE) is -91.89% and return on invested capital (ROIC) is -42.03%.
| Return on Equity (ROE) | -91.89% |
| Return on Assets (ROA) | -37.60% |
| Return on Invested Capital (ROIC) | -42.03% |
| Return on Capital Employed (ROCE) | -75.11% |
| Weighted Average Cost of Capital (WACC) | 13.72% |
| Revenue Per Employee | $42,290 |
| Profits Per Employee | -$267,968 |
| Employee Count | 31 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.77% in the last 52 weeks. The beta is 1.99, so SCNI's price volatility has been higher than the market average.
| Beta (5Y) | 1.99 |
| 52-Week Price Change | -76.77% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 1.13 |
| Relative Strength Index (RSI) | 47.43 |
| Average Volume (20 Days) | 10,155,852 |
Short Selling Information
The latest short interest is 72,973, so 2.10% of the outstanding shares have been sold short.
| Short Interest | 72,973 |
| Short Previous Month | 83,124 |
| Short % of Shares Out | 2.10% |
| Short % of Float | 2.39% |
| Short Ratio (days to cover) | 1.41 |
Income Statement
In the last 12 months, SCNI had revenue of $1.31 million and -$8.31 million in losses. Loss per share was -$3.56.
| Revenue | 1.31M |
| Gross Profit | -2.65M |
| Operating Income | -7.54M |
| Pretax Income | -8.31M |
| Net Income | -8.31M |
| EBITDA | -6.12M |
| EBIT | -7.54M |
| Loss Per Share | -$3.56 |
Full Income StatementBalance Sheet
The company has $1.66 million in cash and $2.27 million in debt, giving a net cash position of -$606,000 or -$0.17 per share.
| Cash & Cash Equivalents | 1.66M |
| Total Debt | 2.27M |
| Net Cash | -606,000 |
| Net Cash Per Share | -$0.17 |
| Equity (Book Value) | 8.10M |
| Book Value Per Share | 0.71 |
| Working Capital | 469,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$6.03 million and capital expenditures -$24,000, giving a free cash flow of -$6.06 million.
| Operating Cash Flow | -6.03M |
| Capital Expenditures | -24,000 |
| Depreciation & Amortization | 1.42M |
| Net Borrowing | n/a |
| Free Cash Flow | -6.06M |
| FCF Per Share | -$1.75 |
Full Cash Flow StatementMargins
| Gross Margin | -202.29% |
| Operating Margin | -575.29% |
| Pretax Margin | -633.64% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |